title: Lost expression of ADAMTS5 protein associates with progression and poor prognosis of hepatocellular carcinoma.
abstract: Altered expression of ADAMTS5 is associated with human carcinogenesis and tumor progression. However, the role of ADAMTS5 in hepatocellular carcinoma (HCC) is unclear. This study analyzed ADAMTS5 expression in HCC tissues and tested for association with clinicopathological and survival data from HCC patients and then explored the role of ADAMTS5 in HCC cells in vitro. Paraffin blocks from 48 HCC patients were used to detect ADAMTS5 and vascular endothelial growth factor (VEGF) expression and microvessel density (MVD). A normal liver cell line and HCC cell lines were used to detect ADAMTS5 expression and for ADAMTS5 manipulation. ADAMTS5 cDNA was stably transfected into HCC cells and ADAMTS5 expression assessed by Western blot analysis. Tumor cell-conditioned growth medium was used to assess human umbilical vein endothelial cell migration and Matrigel tube formation. Xenograft assay was performed to determine the role of ADAMTS5 in vivo. The data showed that the expression of ADAMTS5 was reduced in HCC, which was inversely associated with VEGF expression, MVD, and tumor size and associated with poor overall survival of HCC patients. Lentivirus-mediated ADAMTS5 expression significantly inhibited tumor angiogenesis by downregulating in vitro expression of VEGF and inhibiting migration and tube formations, and also inhibited tumor growth and VEGF expression and reduced MVD in vivo in a mouse xenograft model. Taken together, these results suggest that ADAMTS5 plays a role in suppression of HCC progression, which could be further studied as a promising novel therapeutic target and a potential prognostic marker in HCC.
authors.affiliation: Cancer Center, Daping Hospital and Research Institute of Surgery, The Third Military Medical University, Chongqing, People's Republic of China ; Department of Biochemistry and Molecular Biology, The Third Military Medical University, Chongqing, People's Republic of China.
authors.forename: Chongyi
authors.initials: C
authors.lastname: Li
authors.affiliation: Cancer Center, Daping Hospital and Research Institute of Surgery, The Third Military Medical University, Chongqing, People's Republic of China.
authors.forename: Yanli
authors.initials: Y
authors.lastname: Xiong
authors.affiliation: Cancer Center, Daping Hospital and Research Institute of Surgery, The Third Military Medical University, Chongqing, People's Republic of China.
authors.forename: Xueqin
authors.initials: X
authors.lastname: Yang
authors.affiliation: Cancer Center, Daping Hospital and Research Institute of Surgery, The Third Military Medical University, Chongqing, People's Republic of China.
authors.forename: Lin'ang
authors.initials: L
authors.lastname: Wang
authors.affiliation: Cancer Center, Daping Hospital and Research Institute of Surgery, The Third Military Medical University, Chongqing, People's Republic of China.
authors.forename: Shiheng
authors.initials: S
authors.lastname: Zhang
authors.affiliation: Cancer Center, Daping Hospital and Research Institute of Surgery, The Third Military Medical University, Chongqing, People's Republic of China.
authors.forename: Nan
authors.initials: N
authors.lastname: Dai
authors.affiliation: Cancer Center, Daping Hospital and Research Institute of Surgery, The Third Military Medical University, Chongqing, People's Republic of China.
authors.forename: Mengxia
authors.initials: M
authors.lastname: Li
authors.affiliation: Cancer Center, Daping Hospital and Research Institute of Surgery, The Third Military Medical University, Chongqing, People's Republic of China.
authors.forename: Tao
authors.initials: T
authors.lastname: Ren
authors.affiliation: Cancer Center, Daping Hospital and Research Institute of Surgery, The Third Military Medical University, Chongqing, People's Republic of China.
authors.forename: Yuxin
authors.initials: Y
authors.lastname: Yang
authors.affiliation: Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL, USA.
authors.forename: Shu-Feng
authors.initials: SF
authors.lastname: Zhou
authors.affiliation: Department of Biochemistry and Molecular Biology, The Third Military Medical University, Chongqing, People's Republic of China.
authors.forename: Lixia
authors.initials: L
authors.lastname: Gan
authors.affiliation: Cancer Center, Daping Hospital and Research Institute of Surgery, The Third Military Medical University, Chongqing, People's Republic of China.
authors.forename: Dong
authors.initials: D
authors.lastname: Wang
mesh_terms: D051722:ADAM Proteins / Q000096:biosynthesis*; D000071116:ADAMTS5 Protein; D000328:Adult; D000368:Aged; D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis*; D002478:Cells, Cultured; D018450:Disease Progression; D005260:Female; D056945:Hep G2 Cells; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis*; D008297:Male; D051379:Mice; D055806:Microvessels / Q000473:pathology; D008875:Middle Aged; D009374:Neoplasms, Experimental / Q000175:diagnosis; D011379:Prognosis; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis; D055815:Young Adult
chemical_list: D042461:Vascular Endothelial Growth Factor A; D051722:ADAM Proteins; D000071116:ADAMTS5 Protein; C121532:ADAMTS5 protein, human
keywords: A disintegrin and metalloproteinase with thrombospondin motifs 5; tumor angiogenesis; tumor cell xenograft
references.citation: Am J Pathol. 2000 Jun;156(6):1887-900
references.pmid: 10854212
references.citation: Am J Pathol. 2012 Sep;181(3):1056-68
references.pmid: 22796434
references.citation: J Biol Chem. 2003 Jun 27;278(26):23656-65
references.pmid: 12716911
references.citation: Clin Cancer Res. 2004 Apr 1;10(7):2429-40
references.pmid: 15073121
references.citation: Prostate. 2005 May 15;63(3):269-75
references.pmid: 15599946
references.citation: Nature. 2005 Mar 31;434(7033):644-8
references.pmid: 15800624
references.citation: Nature. 2005 Mar 31;434(7033):648-52
references.pmid: 15800625
references.citation: Acta Neuropathol. 2005 Sep;110(3):239-46
references.pmid: 16133547
references.citation: Int J Cardiol. 2013 Feb 20;163(2):183-9
references.pmid: 21704393
references.citation: Cancer Lett. 2013 Jun 10;333(2):159-69
references.pmid: 23352645
references.citation: J Biol Chem. 2013 Oct 4;288(40):28620-9
references.pmid: 23963448
references.citation: PLoS One. 2014;9(1):e85840
references.pmid: 24465741
references.citation: Semin Oncol. 2014 Apr;41(2):235-51
references.pmid: 24787295
references.citation: J Clin Pathol. 2014 Nov;67(11):974-9
references.pmid: 25092674
references.citation: Oncogene. 2015 Jun;34(26):3452-62
references.pmid: 25174399
references.citation: Science. 2006 Oct 13;314(5797):268-74
references.pmid: 16959974
references.citation: Cancer Sci. 2007 Dec;98(12):1993-2001
references.pmid: 17892509
references.citation: Biochem Biophys Res Commun. 2008 Jun 27;371(2):215-9
references.pmid: 18433719
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Ann Surg Oncol. 2011 Aug;18(8):2338-47
references.pmid: 21298349
references.citation: Matrix Biol. 2011 Jun;30(5-6):311-7
references.pmid: 21683141
references.citation: PLoS One. 2011;6(7):e21307
references.pmid: 21814544
references.citation: J Clin Oncol. 2005 Oct 1;23(28):7043-9
references.pmid: 16192589
references.citation: Int J Cancer. 2006 Jan 1;118(1):55-61
references.pmid: 16003758
references.citation: Lancet. 2012 Mar 31;379(9822):1245-55
references.pmid: 22353262
references.citation: Int J Oncol. 2012 Sep;41(3):1043-9
references.pmid: 22735305
references.citation: J Cancer Res Clin Oncol. 2003 Jan;129(1):43-51
references.pmid: 12618900